Although I agree with you that investors have been unimpressed with MNTA revenue simply because of the TEVA overhang.
With all the latest surrounding TEVA, and the most recent Amphastar information surrounding their ANDA; I am confident that the FDA is using MNTA version of enoxaparin as the bar that needs to be meet. period. I believe the investors on the sidelines since approval are waking up and the PPS and call activity are reflecting this today.
Market Data 
Markets 
AI
